Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. reported an insider equity transaction by its President on 12/01/2025. The filing shows that 5,126 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $48.91 per share. This type of code indicates shares were withheld or surrendered to cover taxes associated with the vesting of restricted stock units, rather than being sold on the open market.
After this tax-related share cancellation, the reporting officer beneficially owns 784,776 shares of Class A common stock directly. The issuer satisfied the related federal and state tax withholding obligations in exchange for the relinquished shares, leaving the executive with a substantial continuing equity stake in the company.
Hinge Health, Inc.'s Chief Financial Officer reported a routine share disposition related to tax withholding on equity compensation. On 12/01/2025, the reporting person disposed of 8,213 shares of Class A common stock at $48.91 per share in an exempt transaction. After this transaction, the officer beneficially owned 471,665 shares directly.
The company explains that the shares were withheld and cancelled by the issuer to cover federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). This reflects standard administrative handling of equity awards rather than an open-market sale.
HNGE shareholder(s) filed a Form 144 notice to sell Class A common stock. The filing covers a proposed sale of 21,757 Class A shares through Merrill Lynch, with an aggregate market value of
The filing notes that 37,919,155 Class A shares were outstanding at the time of the notice. It also discloses recent sales by affiliated Bessemer Venture Partners funds in
HNGE has a Form 144 notice indicating that a stockholder plans to sell 23,176 shares of Class A common stock through Merrill Lynch on the NYSE, with an approximate sale date of 11/28/2025. The aggregate market value of the shares to be sold is listed as 1,159,958.8, and the total number of Class A shares outstanding is shown as 37,919,155.
The shares to be sold were acquired on 02/04/2020 in a private placement from the issuer for cash. Over the past three months, Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP together sold several Class A share blocks, including 373,955 and 103,160 shares for gross proceeds of 14,976,898 and 4,979,533.2, and 351,045 and 96,840 shares for gross proceeds of 14,059,352 and 4,674,466.8.
Hinge Health, Inc. (HNGE) Chief Financial Officer James Budge reported open-market sales of Class A common stock under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. On November 25, 2025, he sold 15,730 shares at a weighted average price of $46.8822, 27,248 shares at a weighted average price of $47.7669, and 1,611 shares at a weighted average price of $48.2738, across specified price ranges. Following these transactions, Budge beneficially owned 479,878 shares of Hinge Health Class A common stock in direct ownership.
Hinge Health, Inc. (HNGE) President insider sale reported. A company officer filed a Form 4 showing open-market sales of a total of 15,000 shares of Class A common stock on 11/21/2025, executed in three transactions.
The shares were sold at weighted average prices of $44.3538, $45.7528, and $46.0885, within disclosed price ranges from $43.96 to $46.21. The transactions were made under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following these sales, the reporting person directly holds 789,902 shares of Class A common stock.
Hinge Health, Inc. (HNGE)
After this transaction, the director beneficially owns 27,750 shares of Hinge Health Class A common stock directly. No derivative securities transactions were reported in this filing.
HNGE insider Kristina Leslie has filed a Form 144 notice covering the proposed sale of 1,250 shares of HNGE common stock through Morgan Stanley Smith Barney LLC on the NYSE. The shares are valued at an aggregate market value of $57,106.00 based on the filing and are part of a class with 37,919,155 shares outstanding.
The filing shows these shares were acquired as restricted stock from the issuer, with 688 shares acquired on 04/01/2025 and 562 shares on 01/01/2025. Over the prior three months, Leslie reported additional open-market sales of HNGE common stock, including 3,813 shares sold on 11/19/2025 for gross proceeds of $166,257.86 and 2,187 shares sold on 11/18/2025 for $88,476.40.
HNGE filed a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers 15,000 shares of common stock with an aggregate market value of $680,400.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The filing notes that there were 37,919,155 shares or other units outstanding at the time of the notice.
The shares to be sold were acquired as performance stock units from the issuer on 04/01/2023, with 15,000 securities acquired on that date and the payment nature listed as "N/A." The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hinge Health, Inc. (HNGE) reported an insider stock sale by its Chief Financial Officer. On 11/20/2025, the CFO sold 781 shares of Class A common stock at a price of $44.78 per share in an open-market transaction coded as a sale. This transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to help insiders systematically sell shares over time. Following this sale, the CFO beneficially owns 524,467 shares of Hinge Health common stock in direct ownership.